Citius Oncology, Inc. filings document material-event disclosures for an oncology-focused biopharmaceutical company commercializing LYMPHIR™. Recent Form 8-K reports cover operating and financial results following the LYMPHIR launch, international shipment and distribution updates, clinical-study disclosures involving denileukin diftitox-cxdl, and press-release exhibits related to commercial and medical developments.
The filing record also includes emerging growth company disclosures, Nasdaq continued-listing notice reporting, and categories such as material agreements, shareholder voting matters, capital-structure disclosure, governance matters, and security-structure information. These documents frame CTOR’s public reporting around product commercialization, clinical development, corporate governance, listing compliance, and financing-related matters.
Citius Oncology, Inc. reported that its Board of Directors expanded to nine members and appointed Jonathan Peri, Ph.D., J.D. as an independent Class I director, effective August 10, 2026, serving until the 2028 annual meeting or until a successor is elected and qualified. The Board determined that he meets applicable Nasdaq and SEC independence standards, and he will participate in the compensation program for independent directors, which is under review.
The company highlights Dr. Peri’s three decades of leadership in higher education, financial services, law, and governance, including his role as President of Manor College and prior service as chief legal officer of Neumann University and lead advisory board director at First State Bank. Citius Oncology also reiterates that it launched LYMPHIR in December 2025 for adults with relapsed or refractory Stage I–III cutaneous T-cell lymphoma and cites an initial CTCL market for LYMPHIR that management estimates currently exceeds $400 million.
Citius Oncology, Inc. filed a prospectus supplement updating its S-1-based Prospectus after the exercise of 6,818,182 warrants at a reduced exercise price of $0.90 per share under a warrant inducement agreement, generating approximately $6.1 million in net proceeds. The supplement notes that 272,727 placement agent warrants remain outstanding. It also incorporates a Form 8-K and press release describing commercial progress for LYMPHIR, its FDA-approved therapy for relapsed or refractory Stage I–III CTCL.
LYMPHIR is now available in 42 institutions, with new institutional accounts up 78% quarter over quarter and vials ordered up 31%. The initial CTCL market opportunity for LYMPHIR is estimated to exceed $400 million, and management cites near-universal payer coverage and ongoing formulary expansion as key launch indicators.
Citius Oncology, Inc. reported commercial momentum for LYMPHIR, its FDA-approved therapy for relapsed or refractory Stage I–III cutaneous T‑cell lymphoma. During the quarter ended June 30, 2026, new institutions ordering LYMPHIR increased 78% quarter over quarter, while institutional vial orders rose 31%. LYMPHIR was available at 42 institutions, including academic centers, National Comprehensive Cancer Network sites, and community infusion centers, with revenue recognized when wholesale orders are placed and filled.
The company cites near‑universal payer coverage and is targeting formulary inclusion at 100 priority institutions by year‑end, after adding more than 20 additional institutions in the current quarter. Management estimates the initial cutaneous T‑cell lymphoma market for LYMPHIR currently exceeds $400 million, and notes increased engagement with CTCL experts and expanded commercial and medical affairs teams.
LYMPHIR carries a boxed warning for capillary leak syndrome, which occurred in 27% of treated patients, including 0.8% fatal cases, and it is associated with infusion‑related reactions in 69% of patients, visual impairment in 9%, and frequent liver enzyme elevations, alongside embryo‑fetal toxicity risk.
Citius Pharmaceuticals, Inc. filed Amendment No. 4 updating its ownership in Citius Oncology, Inc.. The company remains the beneficial owner of 66,049,615 common shares, with sole voting and dispositive power, representing about 71.0% of Citius Oncology’s outstanding common stock.
The percentage decline from approximately 74.9% reflects an increase in Citius Oncology’s total shares outstanding, not any share purchases or sales by Citius Pharmaceuticals. The filing confirms Citius Pharmaceuticals still holds a clear majority stake and control position in Citius Oncology.
Citius Oncology, Inc. files a Prospectus Supplement to its Form S-1 registering 6,818,182 shares of common stock underlying warrants and noting 272,727 placement agent’s warrants remain outstanding. The supplement states the 6,818,182 warrants were exercised at a reduced exercise price of $0.90 per share, producing net proceeds to the company of approximately $6.1 million. The supplement attaches a Form 8-K furnishing a press release highlighting Phase 1 investigator-initiated data for LYMPHIR® in combination with pembrolizumab, including a 20.5-month median progression-free survival among patients achieving clinical benefit and a 33% objective response rate in relapsed or refractory endometrial cancer in a small cohort. The supplement must be read with the March 2, 2026 prospectus and updates those disclosures.
Citius Oncology, Inc. filed an update describing Phase 1 data for its drug LYMPHIR (denileukin diftitox-cxdl) combined with pembrolizumab in recurrent or refractory gynecologic cancers. In an investigator-initiated study of 25 heavily pre-treated patients, 21 were evaluable for efficacy.
The company reports that 48% of efficacy-evaluable patients (10 of 21) achieved clinical benefit, with a median progression-free survival of 20.5 months in this subgroup, and responses were seen even in patients previously treated with immune checkpoint inhibitors. LYMPHIR showed a manageable safety profile in this setting, according to investigators, though the study was not powered to prove efficacy.
Citius also highlights that LYMPHIR is FDA-approved and launched in the U.S. for adults with relapsed or refractory Stage I–III cutaneous T‑cell lymphoma after at least one prior systemic therapy, with management estimating the initial CTCL market opportunity for LYMPHIR currently exceeds $400 million.
Citius Oncology, Inc. (CTOR) notified stockholders that a majority holder approved, by written consent, potential issuances of common stock tied to a Loan and Security Agreement and several warrant transactions. The Loan Agreement makes up to $25.0 million of term loans available, with $10.0 million funded on May 6, 2026, and contingent tranches of $7.0 million and $8.0 million subject to milestones.
The Company issued lender warrants and investor warrants exercisable only with stockholder approval; lender warrants formula includes a base of $1.0 million plus 10% of funded Tranche 2 and Tranche 3 amounts divided by a $0.90 exercise price. The lender conversion option covers up to $4.0 million of outstanding principal at a $1.08 conversion price. The May Common Warrants allow purchase of 25,555,556 shares; May placement-agent warrants for 894,444 shares; amended December warrants cover 15,697,024 shares. The actions become effective June 18, 2026 and were approved to ensure Nasdaq compliance under Listing Rule 5635(d).
Citius Oncology, Inc. is registering up to 32,931,482 shares of common stock for resale by selling stockholders.
The registration covers (i) up to 25,555,556 shares issuable upon exercise of Purchaser Warrants at an exercise price of $0.90, (ii) up to 894,444 shares issuable upon exercise of Placement Agent Warrants at $1.125, (iii) up to 3,703,704 shares issuable upon conversion of up to $4.0 million of term loans at a conversion price of $1.08, and (iv) up to 2,777,778 shares issuable upon exercise of Lender Warrants at $0.90.
The shares are being registered to satisfy registration rights and will be sold from time to time by the identified selling stockholders; the Company will not receive proceeds from resales but would receive proceeds from any cash exercise of the Warrants. Shares outstanding were 92,981,204 before this registration and would be 125,912,686 after full exercise as assumed in the prospectus.
Citius Oncology, Inc. files a prospectus supplement dated May 15, 2026 that updates its post-effective S-1 registration and attaches the company’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2026.
The supplement states 6,818,182 shares of common stock underlying previously issued warrants were exercised at a reduced exercise price of $0.90 per share pursuant to a warrant inducement agreement, producing approximately $6.1 million of net proceeds to the company. The supplement also confirms 272,727 placement agent warrants remain outstanding. The company reports 92,981,204 shares outstanding as of May 14, 2026 and discloses cash of $2,632,634 as of March 31, 2026.